{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-23-000034","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.347274+00:00","generated_at":"2026-06-15T21:50:21.391477+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Nurix shareholders elect all director nominees; say-on-pay passes with 58.5% support","bullets":["All three Class III directors elected: Sands (97.1%), Kunkel (87.5%), Silva (86.2%) of votes cast.","Ratification of PricewaterhouseCoopers as auditor received 99.9% of votes cast for.","Non-binding advisory say-on-pay approval: 19.9M for, 12.5M against, 1.6M abstain (58.5% support).","Notable 12.5% of votes withheld for Kunkel and 13.8% for Silva, indicating shareholder dissent."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-23-000034","json":"https://secwatch.observer/filing/0001549595-23-000034.json","markdown":"https://secwatch.observer/filing/0001549595-23-000034.md","text":"https://secwatch.observer/filing/0001549595-23-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000034/0001549595-23-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000034/nurix-20230505_8xk2023annu.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:50:21.391477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3287ab3a0371cb22ad28f6952e7a76dcff700110","claim":"Nurix Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending November 30, 2023. at the 2023-05-04 meeting.","evidence_excerpt":"Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm Votes For Votes Against Abstentions Broker Non-Votes 39,212,140 10,575 15,196 — The stockholders ratified the appointment","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000034/0001549595-23-000034-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-04"}],"fact_type":"shareholder_vote"},{"claim_id":"40126f2f7013fbd452c1dbb05cdf3bd1faf38fea","claim":"Nurix Therapeutics, Inc. shareholders approved Election of three Class III directors: Arthur T. Sands, M.D., Ph.D., Lori A. Kunkel, M.D., Paul M. Silva, each to serve a three-year term expiring at the 2026 annual meeting. at the 2023-05-04 meeting.","evidence_excerpt":"Proposal 1. Election of Directors Nominee Votes For Votes Withheld Broker Non-Votes Arthur T. Sands, M.D., Ph.D. 33,080,351 971,642 5,185,918 Lori A. Kunkel, M.D. 29,782,567 4,269,426 5,185,918 Paul M. Silva 29,337,363 4,714,630 5,185,918 Each of the three nominees for director was elected","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000034/0001549595-23-000034-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-04"}],"fact_type":"shareholder_vote"},{"claim_id":"42d9dba6c6bf6f50a72f7db397735151838805bc","claim":"Nurix Therapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. at the 2023-05-04 meeting.","evidence_excerpt":"Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers Votes For Votes Against Abstentions Broker Non-Votes 19,907,448 12,499,830 1,644,715 5,185,918 The stockholders approved","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000034/0001549595-23-000034-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-04"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}